Schlütermann, David <br/><br/>
Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.  [electronic resource] 

 -  Urologic oncology  04 2018 
 - 160.e1-160.e13 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2496 
<br/><br/><label>Standard No.: </label>10.1016/j.urolonc.2017.11.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Autophagy--drug effects<br/>Carcinoma, Transitional Cell--drug therapy<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Cisplatin--pharmacology<br/>Class III Phosphatidylinositol 3-Kinases--antagonists & inhibitors<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Humans<br/>Up-Regulation<br/>Urinary Bladder Neoplasms--drug therapy